Apollomics Announces ~$6M Private Placement Financing; Pursuant To The Terms Of The Subscription Agreements, Co Is Selling An Aggregate Of 19,166,666 Class A Ordinary Shares At A Price Of $0.30/Share
Apollomics Announces ~$6M Private Placement Financing; Pursuant To The Terms Of The Subscription Agreements, Co Is Selling An Aggregate Of 19,166,666 Class A Ordinary Shares At A Price Of $0.30/Share
Apollomics Inc. (NASDAQ:APLM), a clinical-stage biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that it entered into subscription agreements for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $6 million to the Company, before deducting offering expenses. The PIPE financing included participation from both new and existing investors.
Apollomics Inc.（納斯達克股票代碼：APLM）是一家臨床階段的生物製藥公司，正在開發多種抗腫瘤候選藥物，以治療難以治療和耐藥的癌症。該公司今天宣佈，在扣除發行費用之前，其私人投資公募股權（“PIPE”）融資的認購協議預計將爲公司帶來約600萬美元的總收益。PIPE的融資包括新老投資者的參與。
Pursuant to the terms of the subscription agreements, Apollomics is selling an aggregate of 19,166,666 Class A ordinary shares at a price of $0.30 per share. The PIPE financing is expected to close on May 8, 2024, subject to satisfaction of customary closing conditions.
根據認購協議的條款，Apollomics將以每股0.30美元的價格共出售19,1666股A類普通股。PIPE融資預計將於2024年5月8日結束，但須滿足慣例成交條件。
Apollomics intends to use the net proceeds from the PIPE financing, together with the Apollomics' existing cash, cash equivalents, and marketable securities, to fund its pipeline programs, and for general corporate purposes and working capital.
Apollomics打算使用PIPE融資的淨收益以及Apollomics的現有現金、現金等價物和有價證券，爲其管道項目提供資金，並用於一般公司用途和營運資金。